Company intelligence / Profile preview
NovoCodex Biopharmaceuticals
Shaoxing, Zhejiang, Chinanovocodex.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Their Phase 3 study (ACE-Breast-02) for ARX788 met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating greater PFS benefit compared to control. Based on these results, NovoCodex plans to submit an application for marketing approval in China.[4]
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Biological productsSmall molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ambrx Biopharma Inc.WuXi Biologics
Beyond the preview
Go deeper on NovoCodex Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovoCodex Biopharmaceuticals.